[Skip to Content]
[Skip to Content Landing]
Comment & Response
June 2017

Negative Psychosis Prevention Trials

Author Affiliations
  • 1Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, England
JAMA Psychiatry. 2017;74(6):651. doi:10.1001/jamapsychiatry.2017.0185

To the Editor In the wake of the recently published ω-3 polyunsaturated fatty acids multisite trial (NEURAPRO) by McGorry et al1 in JAMA Psychiatry (n = 304), the 3 largest studies of preventive interventions in individuals at ultrahigh risk (UHR) for psychosis have turned out to be negative (Morrison et al,2 n = 288; McFarlane et al,3 n = 292), suggesting that it may not currently be possible to prevent psychosis. However, the actual risk for psychosis in these interventional studies was found to be extremely low, even in the control group (11.2% in the McGorry et al1 study at 1 year, 9% at 2 years in the Morrison et al2 study, and 2.3% at 2 years in the McFarlane et al3 study), implying that these negative findings are likely to be secondary to small statistical power.

×